8FBM

Crystal structure of Cryptosporidium parvum N-myristoyltransferase with bound myristoyl-CoA and inhibitor 1

8FBM の概要

• エントリーDOI: 10.2210/pdb8fbm/pdb
• 分子名称: Glycylpeptide N-tetradecanoyltransferase, TETRADECANOYL-COA, 2-chloro-5-[ethyl(phenyl)sulfamoyl]-N-[2-(2-oxopyrrolidin-1-yl)phenyl]benzamide, ... (8 entities in total)
• 機能のキーワード: nmt, inhibitor, myristoyl-coa, myrcoa, structural genomics, seattle structural genomics center for infectious disease, ssgcid, transferase, transferase-inhibitor complex, transferase/inhibitor
• 由来する生物種: Cryptosporidium parvum
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 105662.50

構造登録者

Staker, B.L.,Fenwick, M.K.,Seattle Structural Genomics Center for Infectious Disease (SSGCID) (登録日: 2022-11-29, 公開日: 2023-05-31, 最終更新日: 2024-09-04)

主引用文献

Fenwick, M.K.,Reers, A.R.,Liu, Y.,Zigweid, R.,Sankaran, B.,Shin, J.,Hulverson, M.A.,Hammerson, B.,Fernandez Alvaro, E.,Myler, P.J.,Kaushansky, A.,Van Voorhis, W.C.,Fan, E.,Staker, B.L.
Identification of and Structural Insights into Hit Compounds Targeting N -Myristoyltransferase for Cryptosporidium Drug Development.
Acs Infect Dis., 9:1821-1833, 2023

PubMed Abstract: Each year, approximately 50,000 children under 5 die as a result of diarrhea caused by , a protozoan parasite. There are currently no effective drugs or vaccines available to cure or prevent infection, and there are limited tools for identifying and validating targets for drug or vaccine development. We previously reported a high throughput screening (HTS) of a large compound library against -myristoyltransferase (NMT), a validated drug target in multiple protozoan parasite species. To identify molecules that could be effective against , we counter-screened hits from the NMT HTS against NMT. We identified two potential hit compounds and validated them against NMT to determine if NMT might be an attractive drug target also for . We tested the compounds against using both cell-based and NMT enzymatic assays. We then determined the crystal structure of NMT bound to Myristoyl-Coenzyme A (MyrCoA) and structures of ternary complexes with MyrCoA and the hit compounds to identify the ligand binding modes. The binding site architectures display different conformational states in the presence of the two inhibitors and provide a basis for rational design of selective inhibitors.

PubMed: 37722671
DOI: 10.1021/acsinfecdis.3c00151

実験手法

X-RAY DIFFRACTION (1.9 Å)